CYP1A1 and prostate carcinoma: Although studies for colorectal and stomach cancer and colorectal adenoma observed no effect modification by NAT2 acetylation genotype or CYP1A1 and CYP1A2 genotype [24–26], statistically significant interactions were found in a case-control study of prostate cancer [27].